$ICU
SeaStar Medical Holding Corp

2021 Q4 Form 10-K Financial Statement

#000156459022013725 Filed on April 06, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $375.4K $1.122M
YoY Change 21320.61%
% of Gross Profit
Research & Development $500.0K $2.766M
YoY Change -31.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $375.4K $1.122M
YoY Change 21320.61%
Operating Profit -$1.122M -$5.236K
YoY Change
Interest Expense $491.0K $1.198M
YoY Change -136.19%
% of Operating Profit
Other Income/Expense, Net $0.00 -$148.0K
YoY Change -192.5%
Pretax Income $115.6K $75.32K
YoY Change -1537.4%
Income Tax $0.00 -$1.000K
% Of Pretax Income 0.0% -1.33%
Net Earnings $115.6K $75.32K -$5.236K
YoY Change -2307.41% -1537.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.63
Diluted Earnings Per Share $8.857K $6.171K
COMMON SHARES
Basic Shares Outstanding 7.239M
Diluted Shares Outstanding 7.239M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.57K $51.57K
YoY Change 34.33%
Cash & Equivalents $51.57K $38.39K
Short-Term Investments
Other Short-Term Assets $301.1K $301.1K
YoY Change 30.43%
Inventory $0.00
Prepaid Expenses $14.82K
Receivables
Other Receivables $58.00K
Total Short-Term Assets $105.9M $352.6K $269.2K
YoY Change 39250.41% 30.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $105.6M $105.6M
YoY Change
Total Long-Term Assets $0.00 $105.6M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $105.9M $352.6K $269.2K
Total Long-Term Assets $0.00 $105.6M $0.00
Total Assets $105.9M $105.9M $269.2K
YoY Change 39250.41% 39250.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $85.00K $90.00K
YoY Change -76.32%
Accrued Expenses $376.7K $190.0K $123.0K
YoY Change 206.18% -72.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $2.380M
YoY Change 11800.0%
Total Short-Term Liabilities $10.93M $376.7K $249.4K
YoY Change 4281.72% 51.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.55M $10.55M
YoY Change
Total Long-Term Liabilities $10.55M $10.55M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.93M $376.7K $249.4K
Total Long-Term Liabilities $10.55M $10.55M
Total Liabilities $10.93M $10.93M $249.4K
YoY Change 4281.72% 4281.79%
SHAREHOLDERS EQUITY
Retained Earnings -$10.57M -$5.236K
YoY Change 201690.87%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.57M $95.00M $19.76K
YoY Change
Total Liabilities & Shareholders Equity $105.9M $105.9M $269.2K
YoY Change 39250.41% 39250.11%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $115.6K $75.32K -$5.236K
YoY Change -2307.41% -1537.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$797.1K -$1.170M -$113.0K
YoY Change 605.26% 934.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.130K -$105.6M
YoY Change
Cash From Investing Activities $8.130K -$105.6M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 674.7K 106.8M 151.4K
YoY Change 345.62% 70405.91%
NET CHANGE
Cash From Operating Activities -797.1K -1.170M -113.0K
Cash From Investing Activities 8.130K -105.6M
Cash From Financing Activities 674.7K 106.8M 151.4K
Net Change In Cash -114.3K 13.18K 38.39K
YoY Change -397.67% -65.66%
FREE CASH FLOW
Cash From Operating Activities -$797.1K -$1.170M -$113.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001831868
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
true
CY2021Q2 dei Entity Public Float
EntityPublicFloat
103914000
CY2021 dei Auditor Firm
AuditorFirmId
206
CY2021 dei Auditor Name
AuditorName
MaloneBailey, LLP
CY2021 dei Auditor Location
AuditorLocation
Houston, Texas
CY2021Q4 us-gaap Cash
Cash
51567
CY2020Q4 us-gaap Cash
Cash
38388
CY2021Q4 lmao Prepaid Insurance And Other Fees
PrepaidInsuranceAndOtherFees
286237
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
230820
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14817
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
105581820
CY2021Q4 us-gaap Assets
Assets
105934441
CY2020Q4 us-gaap Assets
Assets
269208
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
376702
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
123031
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
126413
CY2021Q4 lmao Deferred Underwriting Commissions In Initial Public Offering
DeferredUnderwritingCommissionsInInitialPublicOffering
3622500
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6930740
CY2021Q4 us-gaap Liabilities
Liabilities
10929942
CY2020Q4 us-gaap Liabilities
Liabilities
249444
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24785
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5236
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19764
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269208
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122443
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1122443
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1185940
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
11820
CY2021 us-gaap Profit Loss
ProfitLoss
75317
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19764
CY2021 lmao Units Issued During Period Value New Issues
UnitsIssuedDuringPeriodValueNewIssues
103500000
CY2021 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-105570000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5738000
CY2021 lmao Warrants Classified As Liabilities
WarrantsClassifiedAsLiabilities
-8116680
CY2021 lmao Underwriting Fees And Offering Costs
UnderwritingFeesAndOfferingCosts
-6211902
CY2021 us-gaap Net Income Loss
NetIncomeLoss
75317
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10565501
CY2021 us-gaap Profit Loss
ProfitLoss
75317
CY2020Q4 us-gaap Profit Loss
ProfitLoss
-5236
CY2020Q4 lmao Formation Costs Paid By Related Parties
FormationCostsPaidByRelatedParties
107789
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1185940
CY2021 us-gaap Interest Income Operating
InterestIncomeOperating
11820
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
301054
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
253671
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5236
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1169826
CY2020Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-113025
CY2021 lmao Payments To Acquire Investment In Trust Account
PaymentsToAcquireInvestmentInTrustAccount
105570000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105570000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5738000
CY2021 lmao Proceeds From Notes Related Party
ProceedsFromNotesRelatedParty
25000
CY2020Q4 lmao Proceeds From Notes Related Party
ProceedsFromNotesRelatedParty
126413
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
101141418
CY2021 lmao Repayment From Notes And Advances Payable Related Party
RepaymentFromNotesAndAdvancesPayableRelatedParty
151413
CY2020Q4 lmao Proceeds From Sale Of Stock To Related Party
ProceedsFromSaleOfStockToRelatedParty
25000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106753005
CY2020Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151413
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13179
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
38388
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38388
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51567
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38388
CY2021 lmao Reclassification Of Warrants To Liability
ReclassificationOfWarrantsToLiability
8116680
CY2021 lmao Deferred Underwriting Commissions In Connection With Initial Public Offering
DeferredUnderwritingCommissionsInConnectionWithInitialPublicOffering
3622500
CY2021 lmao Initial Classification Of Class A Shares Subject To Redemption
InitialClassificationOfClassASharesSubjectToRedemption
105570000
CY2021 lmao Class A Issued To Maxim
ClassAIssuedToMaxim
10
CY2021 lmao Class B Dividend Stock Issued To Sponsor
ClassBDividendStockIssuedToSponsor
44
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
0
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of December 31, 2021 and 2020, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2021 us-gaap Malpractice Insurance Coverage Floor
MalpracticeInsuranceCoverageFloor
250000
CY2021 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Warrant Liabilities</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. In accordance with ASC 825-10 “Financial Instruments”, offering costs attributable to the issuance of the derivative warrant liabilities have been allocated based on their relative fair value of total proceeds and are recognized in the statement of operations as incurred.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10,350,000 warrants issued in connection with the IPO (the “Public Warrants”) and the 5,768,000 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised. The fair value of the Public Warrants issued and Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.</p>
CY2021Q4 lmao Offering Costs Total
OfferingCostsTotal
6211902
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3622500
CY2021Q4 us-gaap Other Ownership Interests Offering Costs
OtherOwnershipInterestsOfferingCosts
518402
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-06-30
CY2021Q4 lmao Working Capital Loans
WorkingCapitalLoans
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021 lmao Initial Business Combination Completion Period
InitialBusinessCombinationCompletionPeriod
P18M
CY2020Q4 lmao Principal Amount Borrowed For Expenses Of Ipo
PrincipalAmountBorrowedForExpensesOfIPO
300000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16088000
CY2021 lmao Redemption Of Warrants Description
RedemptionOfWarrantsDescription
if: (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”); (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions); and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price
CY2021 lmao Redemption Of Warrants
RedemptionOfWarrants
18.00
CY2021 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2021-12-31
CY2021 lmao Warrants Expiration
WarrantsExpiration
P5Y
CY2021 lmao Warrant Agreement Description
WarrantAgreementDescription
In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of common shares, all holders of the warrants would be entitled to receive cash for their warrants (the “tender offer provision”).
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1185940

Files In Submission

Name View Source Status
0001564590-22-013725-index-headers.html Edgar Link pending
0001564590-22-013725-index.html Edgar Link pending
0001564590-22-013725.txt Edgar Link pending
0001564590-22-013725-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lmao-10k_20211231.htm Edgar Link pending
lmao-10k_20211231_htm.xml Edgar Link completed
lmao-20211231.xsd Edgar Link pending
lmao-20211231_cal.xml Edgar Link unprocessable
lmao-20211231_def.xml Edgar Link unprocessable
lmao-20211231_lab.xml Edgar Link unprocessable
lmao-20211231_pre.xml Edgar Link unprocessable
lmao-ex311_7.htm Edgar Link pending
lmao-ex312_6.htm Edgar Link pending
lmao-ex321_9.htm Edgar Link pending
lmao-ex322_8.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending